Zenith Epigenetics’ experienced research team has developed a cutting-edge epigenetic platform, generating differentiated, potent, and selective BET inhibitors. Our experienced management team and world-leading clinical collaborators are developing BETi combination therapies for multiple oncology indications. With a strong emphasis on translational medicine – for selecting patients that will benefit most from the therapy – Zenith is a leader in innovative clinical development of epigenetic combination therapies.
Our lead BETi, ZEN-3694, is in Phase 2 clinical development for the treatment of prostate cancer and breast cancer, the latter in collaboration with Pfizer.
Zenith Captial Corp. held its annual general meeting on January 15, 2025. The comapny organized a live webcast of the event, which included a presentation by President and CEO Donald McCaffrey.
A replay of the webcast will be available for one month following the conclusion of the event, and may be accessed using the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=xHIoxeIO.
Zenith Capital Corp. President & Chief Executive Officer, Donald McCaffrey, presented on the Emerging Growth Conference on September 25, 2024.
This live, interactive online event gave existing shareholders and the investment community the opportunity to interact with Mr. McCaffrey in real time.
You can watch a video of the presentation HERE
